SVB Securities analyst Joseph Schwartz downgraded Design Therapeutics to Market Perform from Outperform with a $6 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DSGN:
- Multiple Downgrades Send Design Therapeutics (NASDAQ:DSGN) Down in Flames
- Design Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Design: Variability of results limited utility of FXN protein measurement
- Design Therapeutics reports Q2 EPS (36c), consensus (40C)
- Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia